April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
The Safety of Infliximab in Behcet’s Disease With Refractory Uveoretinitis
Author Affiliations & Notes
  • Y. Yamada
    Ophthalmology & Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan
  • S. Sugita
    Ophthalmology & Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan
  • T. Kawaguchi
    Ophthalmology & Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan
  • M. Miyanaga
    Ophthalmology & Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan
  • M. Mochizuki
    Ophthalmology & Visual Science, Tokyo Medical and Dental University, Bunkyo-ku, Japan
  • Footnotes
    Commercial Relationships  Y. Yamada, None; S. Sugita, None; T. Kawaguchi, None; M. Miyanaga, None; M. Mochizuki, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5265. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Yamada, S. Sugita, T. Kawaguchi, M. Miyanaga, M. Mochizuki; The Safety of Infliximab in Behcet’s Disease With Refractory Uveoretinitis. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5265.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the safety of infliximab treatment in patients with Behcet’s disease with refractory uveoretinitis.

Methods: : Clinical charts of 36 consecutive patients with Behcet’s disease treated with infliximab at our hospital were retrospectively reviewed. Side effects during the whole follow up period under infliximab (1-49 months: average 18months) were recorded.

Results: : Side effects were observed in 21 patients (58%): dermatological events (9 patients; infusion reaction not included), infusion reaction (8), enteritis (3), leucopenia (2), tuberculosis (1), bacterial pneumonia (1), cellulitis (1), myalgia (1), transaminases increase (1). Serious side effects were observed in 2 patients (6%), which included tuberculosis (n=1) and bacterial pneumonia (n=1). Of the 8 patients who caused infusion reaction, 6 patients had mild-severe acute episodes of uveitis. Eight patients (22%) discontinued the therapy due to infusion reaction in two, move to distance cities in two, and one each due to tuberculosis, bacterial pneumonia, leucopenia, increase of transaminases values.

Conclusions: : The majority adverse events in patients treated with infliximab were mild. However, a much longer observation is necessary to ensure its safety, especially infections.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×